following a full submission:
relugolix, estradiol, norethisterone acetate film-coated tablets (Ryeqo®) is accepted for use within NHSScotland.
Indication under review: in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Relugolix, estradiol, norethisterone acetate film-coated tablets (Ryeqo®), compared with placebo, resulted in statistically and clinically significant improvements in treatment response (menstrual and non-menstrual pelvic pain) after 24 weeks in women with moderate-to-severe pain associated with endometriosis.
Medicine details
- Medicine name:
- relugolix / estradiol / norethisterone acetate (Ryeqo)
- SMC ID:
- SMC2666
- Indication:
In adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
- Pharmaceutical company
- Gedeon Richter UK Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 January 2025